MedTrace Logo

Safety and Pharmacokinetics Study of a New Drug for Type 2 Diabetes

NCT02686281 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2016-04-19

No results posted yet for this study

Summary

The purpose of this study is to determine the toxicity, tolerability and safety of single ascending doses of GMC-252-L-Lysine Salt in healthy male subjects.

Conditions

  • Healthy

Interventions

DRUG

GMC-252-L-Lysine

OTHER

Placebo

Sponsors & Collaborators

  • Simbec Research

    collaborator INDUSTRY

  • Genmedica Therapeutics S.L.

    lead INDUSTRY

Principal Investigators

  • Salvatore Febbraro, MBBS · Simbec Research

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-07-31
Completion
2014-04-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02686281 on ClinicalTrials.gov